A definitive guide for manufacturers, formulators, and business leaders navigating the shift from paper licences to digital, evidence-based approvals.

The Day the Rules Quietly Changed

For decades, an Ayurvedic manufacturing licence was treated almost like a family heirloom. A company acquired it once, framed it, and often ran hundreds of products under the shelter of that single document for thirty years without anyone at the licensing authority ever asking, "But what exactly is inside this bottle, and how do you know it stays safe until the expiry date printed on it?"

That era is ending. Not with a dramatic announcement, but with a steady administrative shift that most of the industry is only now waking up to: the move toward SKU-wise, evidence-backed product approvals routed through the e-Aushadhi digital ecosystem and reinforced by the compliance expectations flowing out of Rule 158B of the Drugs and Cosmetics Rules.

If you manufacture, market, or private-label Ayurvedic, Siddha, or Unani products in India, this is the most consequential change to hit the sector in a generation. This article explains not just what is changing, but why the Government is doing it, what it means commercially, and how a responsible manufacturer should prepare.

Did You Know? The word "e-Aushadhi" is used in two different ways in the market. Historically, "e-Aushadhi" referred to a supply-chain and inventory management platform used by state drug warehouses (particularly for procurement and distribution of medicines to government facilities). More recently, "e-Aushadhi" has become industry shorthand for the broader push toward digital licensing and online product approval systems for the AYUSH sector. When people in the trade say "you now have to go through e-Aushadhi," they are usually pointing at this wider movement toward digitised, product-level regulatory approval — not just warehouse software.

To Understand the Future, You Must Understand the Past

The old world: one licence, unlimited ambiguity

To appreciate why this transformation matters, picture the regulatory landscape as it existed for most of the last forty years.

A manufacturer applied to the State Licensing Authority (the AYUSH or Drug Controller wing of the state) for a licence to manufacture Ayurvedic medicines. Broadly, products fell into two buckets:

• Classical / Shastriya medicines — formulations that appear in the authoritative Ayurvedic texts listed in the First Schedule of the Drugs and Cosmetics Act (think of a classical Chyawanprash, a Triphala Churna, an Ashwagandha preparation made strictly to a textbook formula). These were largely permitted on the strength of the text itself.

• Patent or Proprietary medicines — original formulations combining ingredients mentioned in authoritative texts but in a novel composition or for a novel indication. These required a specific approval.

Once a licence was granted, the practical reality was loose. Product lists grew. New SKUs appeared. Formulations evolved. Yet the regulatory paperwork frequently did not keep pace with what was actually rolling off the production line.

Expert Insight The single biggest misconception in the industry is the belief that "I have a manufacturing licence, therefore every product I make is automatically approved." A manufacturing licence authorises you to operate a facility that makes a category of medicine. It has never been a blanket, permanent, product-by-product safety endorsement. The new system simply makes explicit what was always implicit.

The "legacy licence" problem

Here is where the phrase legacy licence enters the story — and why it is causing anxiety across boardrooms.

A legacy licence is, in plain terms, an older manufacturing approval granted under the earlier, looser regime, under which a large number of products may have been added or manufactured over the years without each one being backed by the level of documentation, stability data, and product-specific approval that regulators now expect.

The legacy licence is not "illegal." It was perfectly valid under the rules of its time. The challenge is that the definition of adequate evidence has moved on, and legacy portfolios are now being asked to demonstrate what they may never have formally compiled: shelf-life data, stability studies, batch consistency records, and product-level approval trails.

Regulatory Note When you hear that a licence needs to be "regularised" or "migrated," what is being asked is essentially this: bring the documentation for each product up to the current evidentiary standard, and register it in the digital approval system so that the authority — and eventually the consumer — can trace it. This is a documentation and evidence exercise, not necessarily a condemnation of the underlying product.

Why the Government Changed the System

No regulator changes a forty-year-old habit for fun. Several powerful forces converged.

1. The industry outgrew the informal model

Indian Ayurveda is no longer a cottage industry of local vaidyas dispensing hand-ground churnas. It is a multi-billion-rupee sector with mass-manufactured SKUs, national distribution, e-commerce, celebrity brands, and exports. When a product is made at industrial scale and sold to millions of strangers who will never meet the formulator, "trust me, it's traditional" is no longer a sufficient safety architecture. The regulatory system had to industrialise to match the industry.

2. Consumer safety and the credibility of Ayurveda itself

Every adulteration scandal, every heavy-metal contamination headline, every "this syrup was found to contain undeclared allopathic drugs" story damages not just one company but the entire category's credibility — domestically and, crucially, in export markets that are already sceptical of traditional medicine. Evidence-based approval is, in part, a defensive shield for the reputation of Ayurveda as a whole.

3. The demand for traceability and transparency

Modern governance runs on data. A paper file in a district office cannot be aggregated, searched, cross-referenced, or audited at national scale. A digital record can. The shift to platforms like e-Aushadhi is part of a much larger "Digital India" governance philosophy: if it isn't in the system, it effectively didn't happen.

4. Alignment with pharmaceutical-grade expectations

For years, allopathic (modern) pharmaceuticals have operated under rigorous product-level scrutiny — stability data, defined shelf life, batch records, GMP audits. Ayurveda was held to a gentler standard. As the two worlds increasingly compete on the same pharmacy shelves and the same e-commerce pages, the regulatory gap became harder to justify. The direction of travel is clear: Ayurvedic regulation is moving closer to pharmaceutical-grade discipline, even if it will always retain features unique to traditional medicine.

Industry Perspective Think of it the way food regulation evolved. Twenty-five years ago, a packaged snack could carry vague labelling. Then FSSAI arrived, and suddenly every product needed a licence number, a defined shelf life, nutritional disclosure, and traceable manufacturing. The food industry panicked — and then the organised players realised the new rules were the best thing that ever happened to them, because compliance became a moat that low-quality operators couldn't cross. Ayurveda is at that same inflection point right now.

What the New System Actually Requires

Let us translate the shift into concrete expectations. The move is toward:

SKU-wise (product-by-product) approval

Instead of one licence covering an undifferentiated basket of products, the expectation is increasingly that each distinct product — each SKU — is individually accounted for, with its own formulation record, its own specifications, and its own evidence file. A 60-tablet immunity blend and a 200 ml digestive tonic are two different products with two different risk profiles, and the system now wants to see them as such.

Evidence of safety and shelf life

The heart of the change. A product-level approval increasingly expects:

• A defined, documented formulation (ingredients, quantities, sourcing standards).

• Specifications for raw materials and finished goods.

• Stability data justifying the shelf life printed on the label (covered in depth in the companion article on stability studies).

• Batch manufacturing records demonstrating consistency and reproducibility.

• Compliant labelling and claims.

Digital submission and traceability

Documentation flows into a digital approval environment rather than a physical file. This enables:

• Transparency — the authority can see what was approved and on what basis.

• Traceability — a product on a shelf can, in principle, be traced back to its approval.

• Inspection readiness — auditors can pull records rather than rely on a manufacturer producing a dusty binder.

Practical Tip Do not treat "getting the approval" as the finish line. The approval is the entry ticket. What auditors increasingly want to see is that the evidence behind the approval is live and maintained — that your stability programme is ongoing, your batch records are current, and your specifications are being met batch after batch. Compliance is a subscription, not a one-time purchase.

Where QR Codes and the Digital Future Fit In

A recurring theme in modern pharmaceutical and AYUSH policy discussions is track-and-trace, often implemented through QR codes or barcodes on packaging. The regulatory logic runs in a straight line:

1. If every product has a digital approval record, and

2. every pack carries a scannable code linking to that record, then

3. a consumer, chemist, inspector, or export partner can instantly verify authenticity and provenance.

This is the endgame the digital shift is building toward: a world where a counterfeit or unapproved product is exposed the moment someone scans it, and where a genuine, well-documented manufacturer can prove their legitimacy at the point of sale.

Future Watch Expect the direction of policy to keep tightening the link between the physical pack in a consumer's hand and the digital record in a Government database. Manufacturers who build clean, structured, digital-first documentation today will find themselves effortlessly compliant when the next layer of track-and-trace requirements arrives. Those who treat documentation as an afterthought will be perpetually retrofitting.

The Industry Impact: A Tale of Two Manufacturers

This transformation does not land evenly. It creates winners and losers, and the dividing line is not size — it is mindset.

The unorganised / under-documented operator

For a manufacturer who has run on a legacy licence with thin documentation, low-cost operations, and a "we've always done it this way" culture, the new system is an existential shock. Compiling stability data, building specifications, and migrating an entire legacy portfolio into a digital, evidence-backed format is expensive, slow, and culturally alien. Some of these operators will exit, consolidate, or become contract clients of larger players.

The organised, compliance-ready manufacturer

For a manufacturer who already runs proper GMP, maintains batch records, invests in a QC laboratory, and treats documentation as a discipline, the new system is a competitive gift. The barriers that frustrate weaker rivals become the moat that protects the strong.

CEO Takeaway Regulation always redistributes market share from those who resist it to those who anticipate it. The question every Ayurvedic business leader should be asking is not "How do I survive these rules?" but "How do I turn compliance into my most defensible competitive advantage before my competitors do?"

Opportunities the change creates

• Premium positioning: "Fully approved, fully documented, stability-tested" becomes a genuine differentiator, especially for private-label and export clients.

• B2B trust: Brands looking for a contract manufacturer will increasingly screen for regulatory maturity before signing. Documentation becomes a sales asset.

• Export readiness: The same evidence discipline that satisfies Indian regulators is the foundation for entering regulated foreign markets.

• Consolidation upside: As weaker players exit, well-run manufacturers absorb their volumes.

Challenges to be honest about

• Real cost and time to build stability programmes and migrate legacy portfolios.

• A shortage of trained regulatory and QC talent in the AYUSH space.

• The learning curve of digital submission systems.

• Cash-flow strain for SMEs during the transition.

How Ayurveda's Regulation Compares to Pharmaceuticals

A useful mental model: Ayurveda is walking the path pharmaceuticals walked decades ago, but on its own terms.

The key nuance: Ayurveda will not simply become pharma. Classical formulations, textual authority, and traditional wisdom remain central. But the evidentiary and documentary discipline of pharma is being layered on top. Manufacturers who understand this hybrid — respect the tradition, adopt the rigour — will lead.

Common Mistake Assuming that because a formulation is "classical" and "time-tested," it is exempt from modern documentation. Textual pedigree may support the formulation's legitimacy, but it does not automatically supply your product's stability data, your batch consistency, or your labelling compliance. Tradition explains the recipe; it does not audit your factory.

How a Responsible Manufacturer Should Prepare

Here is a pragmatic sequence — the order matters.

Inspection & Preparation Checklist

Step 1 — Portfolio audit. List every product you actually manufacture and sell. Map each to its licence basis (classical vs proprietary) and flag anything running on thin or missing documentation.

Step 2 — Classify and prioritise. Rank SKUs by volume, revenue, and risk. Fix your high-volume, high-revenue, higher-risk products first.

Step 3 — Build the evidence file per SKU. For each priority product, assemble: formulation record, raw-material and finished-goods specifications, batch records, and — critically — a stability study plan.

Step 4 — Launch a stability programme. You cannot retroactively invent stability data. Start real-time and accelerated studies now so the data exists when you need it. (See the dedicated stability article.)

Step 5 — Digitise. Move from binders to structured, retrievable digital records aligned with how approvals are now submitted and audited.

Step 6 — Fix labelling and claims. Ensure every label matches the approved formulation and carries compliant claims — a frequent, avoidable audit failure.

Step 7 — Build inspection readiness. Run internal mock audits. The best time to discover a gap is before an inspector does.

Preparation Checklist — the five questions an inspector may ask about any product

1. Show me the approved formulation for this SKU.

2. Show me the specifications and how you test against them.

3. Show me the stability data that justifies this expiry date.

4. Show me batch records proving consistency across production.

5. Show me that the label matches everything above. If you can answer all five for every product, you are ready. If you cannot, you have a project plan.

The Government's Long-Term Vision (and What It Means for You)

Read the direction of travel and the destination becomes obvious. The Government is building toward an Ayurvedic sector that is:

• Digitally governed — every product a traceable record.

• Evidence-based — safety and shelf life demonstrated, not assumed.

• Globally credible — capable of standing up to the scrutiny of export markets.

• Consumer-protective — where authenticity can be verified at the point of purchase.

• Consolidated around quality — rewarding manufacturers who invest in compliance.

Future Watch The likeliest trajectory over the coming years: tighter product-level approval, deeper stability expectations, wider track-and-trace, and steadily rising alignment with international quality norms. Every one of these trends rewards the same behaviour — early, structured, digital, evidence-based documentation. You do not need to predict each specific rule to prepare for all of them. You need to build the underlying discipline once.

How ASLI Ayurveda Has Prepared Itself

ASLI Ayurveda has approached this transformation not as a compliance burden to be survived, but as the defining opportunity of the next decade of Ayurvedic manufacturing.

Rather than waiting for enforcement to force change, ASLI has built its operating model around the assumption that every product will one day need to prove itself — its formulation, its stability, its consistency, and its authenticity. That means:

• Treating documentation as a core deliverable, not an afterthought — so that clients receive not just a manufactured product, but a defensible evidence file behind it.

• Investing in stability study planning and shelf-life validation as a standard part of product development, so that expiry dates are backed by data.

• Building digital-first, retrievable records designed to align with how modern approvals are submitted and audited.

• Supporting brand partners — particularly private-label and third-party clients — through the regulatory pathway, from formulation and specification to approval, labelling compliance, and inspection readiness.

The goal is simple: when a brand chooses ASLI, they are not just renting a production line. They are gaining a partner who has already done the hard thinking about where Ayurvedic regulation is heading — and who can help them arrive there ahead of the curve.

CEO Takeaway The manufacturers who thrive in the next decade will be those who understood, early, that in a digital and evidence-based regime, the product is only half of what you sell — the other half is the proof.

A Note on Where to Draw the Lines

This article distinguishes deliberately between three things, and you should too:

• Regulatory requirements — what the rules formally demand. These are evolving; always verify the current position with the relevant authority or a qualified regulatory consultant before acting.

• Industry best practices — what leading, responsible manufacturers do because it is prudent, even where not strictly mandated.

• Informed interpretation — the analysis in this article of where things are heading and why, offered to help you plan.

Where this article discusses scientific principles (such as stability), it explains the underlying rationale rather than presenting interpretation as official policy. Regulatory specifics vary by state, product category, and time — treat this as a strategic map, not a substitute for authoritative confirmation.

Frequently Asked Questions

Q: Does my old manufacturing licence become invalid?

Not automatically. A legacy licence remains valid, but the expectation is increasingly that the products under it are brought up to current documentation and approval standards. Think "regularise and register," not "start from zero."

Q: Does every single product now need separate approval?

The direction is toward product-level (SKU-wise) accountability. The precise mechanics depend on product category (classical vs proprietary) and current rules in your state — confirm specifics with your licensing authority.

Q: Do classical formulations need stability data?

Textual authority supports the formulation, but your specific manufactured product still needs to justify its labelled shelf life and demonstrate consistency. Best practice is to hold stability data regardless of category.

Q: How long does it take to prepare?

The binding constraint is usually stability data, which is time-based — real-time studies literally take real time. Starting early is the single most valuable thing you can do.

Q: Is this the same as pharmaceutical regulation?

It is moving toward pharmaceutical-grade discipline while retaining Ayurveda's distinct features. Similar rigour, different foundations.

A Different Kind of Invitation

If you manufacture, market, or private-label Ayurvedic products, the questions in this article are not rhetorical — they are the questions your business will need to answer, sooner than most expect.

The purpose here is not to alarm, but to equip. Responsible Ayurveda is stronger, more credible, and more globally competitive when it embraces evidence and transparency. If you are working through what this transformation means for your portfolio — your legacy products, your stability planning, your documentation, or your path to product-level approval — that is precisely the kind of conversation ASLI Ayurveda exists to support.

Consider us a long-term knowledge partner in building an Ayurvedic industry that manufactures not just products, but trust.